Purpose: This study investigated the predictive factors for progression from seizure-related endosulfan poisoning to status epilepticus (SE) and refractory SE (RSE). This study also investigated delayed neurologic sequelae in seizure-related endosulfan poisoning. Methods: This retrospective, observational case series consisted of 73 patients who developed at least one seizure after endosulfan ingestion. Results: The progression rates from seizure-related endosulfan poisoning to SE and from SE-related endosulfan poisoning to RSE were 78.1% and 54.4%, respectively. The SE and RSE fatality rates were 19.2% and 41.9%, respectively. No patients reported the development of delayed neurological sequelae at least six months after discharge. Glasgow coma scale (GCS) score were identified as an independent factor for progression from seizure-related endosulfan poisoning to SE and from SE-related endosulfan poisoning to RSE. Lorazepam administration was independently associated with preventing progression from SErelated endosulfan poisoning to RSE. Conclusion: Seizure-related endosulfan poisoning had higher progression rates to SE and RSE and higher fatality rates than other drug-induced seizures. However, delayed neurologic sequelae after discharge were not demonstrated. Due to the high progression rates from seizure-related endosulfan poisoning to SE and RSE and the absence of an established treatment for SE-related endosulfan poisoning, physicians should aggressively treat patients who experience a seizure after endosulfan poisoning and who present with decreased GCS score. Lorazepam should be considered a first-line anti-epileptic drug for controlling seizures in patients with endosulfan poisoning.
Introduction
Endosulfan is classified as a highly toxic pesticide (Class I) in the EPA's toxicity classification and as a moderately hazardous pesticide (Class II) in the WHO's acute hazard classification [1] . Because it is a threat to human health and the environment, endosulfan is banned or being phased out in several countries, such as the USA, Sri Lanka, and South Korea. However, endosulfan poisoning still occurs due to stocks of endosulfan that existed prior to the implementation of the ban in these countries [2, 3] . In addition, intentional fatal endosulfan poisoning has been reported in countries where endosulfan is currently used such as India and Israel [4] .
Seizures are a common manifestation of endosulfan poisoning, with an incidence rate greater than 70% [1, 3, 4] . Endosulfan causes seizures by reducing the influx of chloride ions into neurons and by blocking the effect of gamma aminobutyric acid (GABA) binding at the GABAA receptor-chloride ionophore complex in the central nervous system [5] . Reduced brain perfusion and oxygenation due to hypotension and respiratory failure induced by endosulfan can contribute to the development of seizures [5] .
Most drug-induced seizures are self-limited and do not cause permanent sequelae [6] . However, recent studies have demonstrated that 25% of cases of seizure-related endosulfan poisoning progress to refractory status epilepticus (RSE) [1, 3] . The most common causes of death in endosulfan poisoning are status epilepticus (SE)-related complications, including RSE [1, 3, 4, 7] . Benzodiazepines (BZDs) are recommended as a first-line agent for SE, but subsequent treatments for SE that are resistant to BZD have not been clearly established [8] . Furthermore, the prompt administration of a high-dose anti-epileptic drug (AED) has been found to be ineffective in controlling RSE-related endosulfan poisoning [9] . In the absence of established treatment guidelines for SE following endosulfan poisoning, early recognition of the risk of SE, rapid seizure control, and preventing medical complications with good supportive care are key factors in reducing fatalities following endosulfan poisoning.
The literature concerning SE-related endosulfan poisoning is limited to case reports [2, 4, [9] [10] [11] . No English-language studies providing information to clinicians regarding the predictive factors for SE and RSE following seizure-related endosulfan poisoning in humans are available. Furthermore, some studies have detected motor deficiencies, neurocognitive alterations and conduct disorders as sequelae after SE [12] . Physicians question whether SErelated endosulfan poisonings have the potential to cause postdischarge epilepsy and neurological impairment.
This study aimed to evaluate the predictive factors for progression to SE and RSE in cases of seizure-related endosulfan poisoning and to demonstrate the clinical outcomes of seizurerelated endosulfan poisoning. Additionally, we investigated whether seizure-related endosulfan poisoning may result in the delayed neurologic sequelae after discharge.
Methods

Study design
This investigation was a single institution, retrospective, observational case study that was performed based on chart reviews. The study design was approved by the Institutional Review Board of Chonnam National University Hospital (IRB No CNUH-2016-229).
Subjects
The following patients were included in the study: patients who were at least 18 years of age, patients who presented to our emergency department (ED) within 24 h after endosulfan ingestion between January 2001 and May 2016 and patients who experienced at least one seizure during their hospitalization. Because delayed neurologic sequelae was one of the outcomes analyzed in this study, patients who presented to the ED at least six months ago were included. To be included, patients had to have experienced seizures related to endosulfan intoxication. Endosulfan poisoning was diagnosed based on a history of endosulfan ingestion that was provided by the patient or family members. Additionally, for patient inclusion, hospital records that indicated the brand of endosulfan insecticide were necessary. The brand was identified through inspection of the bottle or bag that the patient or witness brought to the primary care physician or hospital.
Patients with a history of epilepsy or co-ingestion with another drug, patients transferred before their final outcome was established or patients discharged against medical advice were excluded from the study. Additionally, patients who were deceased upon arrival and who were resuscitated were excluded because of concurrent hypoxic encephalopathy.
Patients with seizure-related endosulfan poisoning were classified into the following two groups according to whether they progressed to SE: a group with seizures and a group with SE. The group with SE was subsequently divided into the following two groups according to whether group members progressed to RSE: a group with non-RSE and a group with RSE. SE was defined as a seizure lasting longer than 5 min or as repeated, discrete seizures without recovery of consciousness between episodes [13] . RSE was defined as seizures that do not respond to two different AEDs [8] . Because RSE was defined based on the number of AEDs administered, we checked whether the recommended AED dose was administered before another AED was administered. The SE treatment guidelines suggested by the Neurocritical Care Society were used to judge the sufficiency of the administered AED dose [14] . None of the participants received lower than the recommended AED dose before receiving another AED. All of the AEDs were administered intravenously.
All of the patients in this study received general supportive measures, including seizure and airway management, mechanical ventilation and/or vasopressor administration, if needed. The choice of AED for seizure management, the need for mechanical ventilation, and the administration of a vasopressor were at the discretion of the on-call emergency physician.
Data collection
Data regarding age, gender, underlying disease, ingestion cause, time interval from ingestion to arrival at our ED, initial Glasgow coma scale (GCS) value, Acute Physiology and Chronic Health Evaluation (APACHE) II score upon presentation, laboratory and electrocardiographic findings upon presentation, seizure characteristics, decontamination, complications during hospitalization, Glasgow outcome scale (GOS) value upon discharge, and delayed neurological sequelae (the development of seizures or deterioration of GOS after discharge) were collected.
The investigated complications included respiratory failure, hypotension, acute renal failure, metabolic acidosis and in-hospital cardiac arrest. Respiratory failure was defined as acute respiratory insufficiency requiring mechanical ventilation support, and acute renal failure was defined as renal failure requiring renal replacement therapy. Hypotension was defined as the need for intravenous vasopressor infusion to ensure blood pressure maintenance after admission. Metabolic acidosis was defined as an arterial pH less than 7.2, a bicarbonate level less than 22 mmol/L, a base concentration of a maximum of 5 mmol/L, and an expected partial pressure of carbon dioxide equal to bicarbonaturia Â 1.5 + 8 AE 2 mmHg.
The seizure characteristics were determined and included type of seizure, type of administered AED, dosage of administered AED, duration of AED administration, and progression to SE and RSE.
To assess delayed neurologic sequelae, patients or family members of patients who survived at discharge were contacted via phone regarding the development of seizure or GOS deterioration after discharge. In the event that a patient or his or her family members could not be contacted and the patient visited our hospital for other medical reasons, the neurologic sequelae were determined by referring to the patient's medical record. Because the last time a patient with endosulfan poisoning visited our ED was in May 2016, the neurologic sequelae of the patients were determined at least six months after the time of endosulfan poisoning.
Data analysis
The baseline patient characteristics are presented as frequencies for categorical variables and as the means and standard deviations or medians and interquartile ranges for continuous variables. The differences in continuous variables between two groups were tested using Student's t-test or the Mann-Whitney test according to the normality of the data. The differences among three groups were tested by ANOVA or the Kruskal-Wallis H test according to the normality of the data. The normality of continuous variables was tested using the Shapiro-Wilk test. For continuous variables analyzed by the Kruskal-Wallis H test, a post-hoc comparison was conducted using the Mann-Whitney test with Bonferroni's adjustment. Fisher's exact test or the chi-square test was performed to test for group differences in the categorical variables. Variables yielding p-values less than 0.05 in the univariate analyses were included in the multivariate logistic regression model to identify independent factors related to progression to SE or RSE following an endosulfan-related seizure. If a selected independent factor was a continuous variable, a receiver operating characteristic (ROC) curve was used to obtain the area under the curve (AUC) with a 95% confidence interval (CI) as well as the sensitivity and specificity of the factor. The Youden index (sensitivity + specificity-1) was obtained, and the maximal Youden index was selected as the optimal cut-off value for the independent factor. P-values less than 0.05 were considered significant. All of the statistical analyses were performed using the Statistical Package for the Social Sciences version 21.0.
Results
Of the 84 patients who presented to the ED after ingesting endosulfan and who did not satisfy any exclusion criteria, 73 (86.9%) experienced at least one endosulfan-related seizure (Fig. 1) . Of these 73 patients, 57 (78.1%) experienced progression to SE (Fig. 1) .
To identify the predictive factors for the risk of SE from seizurerelated endosulfan poisoning, the baseline characteristics, initial clinical features, and seizure characteristics of the group with seizures and the group with SE were compared (Tables 1 and 2 ). The group with SE had lower GCS scores and pH values and higher WBC counts, alanine aminotransferase (ALT) levels, creatinine (Cr) levels, lactate concentrations, and APACHE II scores than the group with seizures. In addition, the frequency of intentional ingestion was higher in the group with SE than in the group with seizures.
GCS scores (OR = 0.628, 95% CI = 0.488-0.809, p-value < 0.001) were selected as an independent factor for progression from seizures related to endosulfan poisoning to SE in the multivariate analysis (Table 3 ). The optimal cut-off GCS score for the risk of SE in seizure-related endosulfan poisoning was 9.5 (AUC = 0.886, 95% CI = 0.774-0.998, sensitivity = 80.0%, specificity = 90.7%).
To predict progression to RSE from SE, we subdivided the 57 patients with SE into the following two groups according to whether they progressed to RSE: a group with non-RSE and a group with RSE (Tables 1 and 2 ). The group with RSE had a lower GCS at presentation and was less frequently administered lorazepam as a first-line drug for seizures than the group with non-RSE. In the multivariate analysis, GCS (OR = 0.689, 95% CI = 0.516-0.921, p value = 0.012) and lorazepam administration (OR = 0.049, 95% CI = 0.008-0.297 p value = 0.001) were independent factors for progression to RSE (Table 3 ). The optimal cut-off GCS score for the risk of RSE in SE-related endosulfan poisoning was 3.5 (AUC = 0.744, 95% CI = 0.609-0.880, sensitivity = 76.0%, specificity = 72.4%).
To investigate the in-hospital outcomes and delayed neurologic sequelae according to seizure progression, we divided the patients into the following three groups: a group with seizures, a group with non-RSE, and a group with RSE. During hospitalization, the incidences of respiratory failure and hypotension significantly increased when seizures progressed to non-RSE and non-RSE progressed to RSE ( Table 4 ). The group with seizures had a lower incidence of metabolic acidosis than the group with non-RSE and the group with RSE (75.0% in the group with seizures vs. 100.0% in the group with non-RSE, p value = 0.007; 75% in the group with seizures vs. 96.8% in the group with RSE, p value = 0.022) ( Table 4 ). The group with RSE had a higher incidence of acute renal failure than the group with seizures and the group with non-RSE (0% in the group with seizures vs. 25.8% in the group with RSE, p value = 0.026, 0% in the group with non-RSE vs. 25.8% in the group with RSE, p value = 0.005). The group with RSE had a higher fatality rate (41.9%) than the group with seizures (0.0%, p value = 0.002).
For the phone interviews, we successfully contacted six (37.5%) of the 16 survivors in the group with seizures, 13 (61.9%) of the 21 survivors in the group with non-RSE, and 13 (72.2%) of the 18 survivors in the group with RSE. No patients reported the Progression to SE (status epilepticus) from seizure*: 73 patients with seizure-related endosulfan poisoning were divided into two groups according to progression to SE: a group with seizures and a group with SE. Progression to RSE (refractory status epilepticus) from SEy: 57 patients with SE-related endosulfan poisoning were divided into two groups according to progression to RSE: a group with non-RSE and a group with RSE. GTC type seizurez: generalized tonic clonic seizure. Duration of AED x (h): the time interval between initial AED administration and discontinuation without seizure recurrence.
development of delayed neurologic sequelae after discharge (Table 4 ).
Discussion
In the present study, the progression rates of seizure-related endosulfan poisoning to SE and RSE were 78.1% and 54.4%, respectively. In contrast, the progression rate to SE following other drug-induced seizures has been reported to reach 10% [7, 13, 15] . Due to its high lipid solubility (log Kow 4.5), endosulfan slowly redistributes back into the circulation over several days [2] . Endosulfan serves as a substrate as well as an inhibitor of the cellular efflux transporter p-glycoprotein, which determines its uptake and efflux [4] . These chemical characteristics can result in endosulfan remaining for a prolonged time in the CNS and, ultimately, in CNS stimulation by endosulfan. In addition, prolonged seizures lead to a decrease in the GABA receptor level secondary to receptor internalization and degradation. These mechanisms may be responsible for the higher refractoriness of the AED-targeted GABA receptor in seizure-related endosulfan poisoning compared with other drug-induced seizures.
In the present study, GCS was identified as an independent predictive factor for progression to SE following seizure-related endosulfan poisoning. However, considering that the observed progression rate of endosulfan-related seizure to SE was 78.1%, predicting the risk of SE may not be very informative for physicians treating patients poisoned with endosulfan. It may be more helpful to distinguish patients with a risk of progression to RSE. The progression rate to RSE from SE-related endosulfan poisoning observed in this study was 54.4%; this rate is higher than the progression rate (9%-44%) of SE-unrelated poisoning to RSE [8, 16] . GCS was identified as an independent factor for progression to RSE from SE. The predictive ability of GCS for RSE in SE is in agreement with previous studies on SE-related non-poisoning and SE-related poisoning [17] . In this study, the optimal cut-off GCS values for the risk of SE from seizures and the risk of RSE from SE were 9.5 and 3.5, respectively. Physicians should consider the prompt and aggressive escalation of a second or third AED if a patient presents with a GCS lower than 9.5 and if the first AED failed to control a seizure following endosulfan poisoning.
Interestingly, the administration of lorazepam as a first-line drug was independently associated with curbing the progression to RSE compared with diazepam. Similar to our results, several studies have shown that lorazepam is superior to diazepam as a first-line drug, with improved seizure outcome and less respiratory depression [18] [19] [20] . The Neurocritical Care Society recently recommended intravenous lorazepam and intramuscular midazolam as first-line drugs for SE based on a consensus statement [14] . To investigate whether the different administered doses of lorazepam and diazepam confounded the superiority of lorazepam, the administered doses of lorazepam and diazepam before the addition of the secondary AED was compared between a group with non-RSE and a group with RSE. There was no difference in the dose of the two AEDs between the two groups: diazepam, 30 (10- 
Table 4
Outcome of endosulfan-related seizures during hospitalization and after discharge. 50) mg in the group with non-RSE vs. 20 mg in the group with RSE, p value = 0.800; lorazepam, 9 (8-11) mg in the group with non-RSE vs. 8 (6) (7) (8) (9) (10) (11) (12) [19, 21] . Furthermore, lorazepam exhibits a tighter binding with GABA receptors. These characteristics of lorazepam may partially contribute to a lower risk of progression from SE to RSE. Although no randomized controlled trial has investigated the effects of specific BZD for seizure-related endosulfan poisoning, we cautiously suggest that lorazepam should be considered prior to diazepam in SE-related endosulfan poisoning. Consistent with the findings of another study showing that patients with RSE exhibit worse outcomes with higher mortality than patients with non-RSE do [17] , the incidences of complications and fatality during hospitalization increased significantly as seizures progressed to RSE in this study. In this study, the fatality rate observed for SE-related endosulfan poisoning was 31.5%, in contrast to a fatality rate of 8.3% for other drug-induced SE [15] . In addition to the SE complication itself, the direct toxic effect of endosulfan on non-CNS organs, such as the myocardium and kidney, and the toxicity of added surfactants may contribute to the higher fatality rate of SE-related endosulfan poisoning compared with that of other drug-induced SE [2, 22] . However, we observed that 32.3% of the group with RSE were discharged with a GOS of 5, and none of the survivors reported deterioration of GOS at least six months post-RSE. In contrast to our results, only 10% of the 63 patients with RSE who had been cared for in a medical or neurointensive care unit performed all usual activities with some symptoms at least six months post-RSE (1 on a modified Rankin Scale) [8] . Our results suggest that RSE-related endosulfan poisoning may have a higher potential for survival without neurologic sequelae despite prolonged RSE compared with RSE related to other etiologies. A prognostic predictor of only RSErelated endosulfan poisoning is needed, and the withdrawal of treatment for RSE-related endosulfan poisoning should be considered based on specific prognostic predictors for RSE-related endosulfan poisoning. Due to the small number of patients with RSE-related endosulfan poisoning in our study, our data could not be analyzed for prognostic factors.
SE results in the persistent overproduction of reactive oxygen species and increased inflammatory mediators, and these changes may contribute to delayed neuropathy [23] . Some studies have suggested that SE alone may result in cognitive impairment independent of the etiology [24] . Thirteen of 32 survivors with RSE experienced declining functional outcomes at follow-up [8] . Therefore, we investigated whether delayed neurologic sequelae develop due to endosulfan-related SE at least six months after discharge. None of the 32 patients who survived reported the development of seizures or deterioration of the GOS after discharge. However, because we simply checked the recurrence of seizures and the deterioration of GOS, it is necessary for further studies to examine neurological changes in detail with regard to motor or cognitive function.
We investigated the duration of AED administration, which was calculated as the time interval between initial AED administration and discontinuation without seizure recurrence (Table 2) . Compared with the 48-h median length of total hospitalization in other drug-related uncomplicated seizures [15] , the group with seizures was administered AED for a longer time (76 h). The longer duration of AED administration in endosulfan poisoning can be explained by the above-mentioned slow redistribution of endosulfan. Because electroencephalogram (EEG) was rarely applied and because this study was retrospective in design, we reported the duration of AED instead of the actual duration of seizures. The duration of administered AED may overestimate the duration of the seizure or SE. However, because pesticide poisoning commonly occurs in rural communities without adequate EEG resources, this time interval may be helpful for determining the withdrawal of AED administration [25] .
The amount of endosulfan ingested was not selected as a predictor for SE-or RSE-related endosulfan poisoning. In cases of poisoning, the ingested amount is not the actual absorbed amount due to vomiting. Furthermore, endosulfan had been commercialized in South Korea as a type of liquid or powder. In the case of ingestion of the powder type of endosulfan mixed with water, the concentration of endosulfan varies depending on the amount of water added. These factors may lead to an inaccurate assessment of the amount of endosulfan ingested.
Endosulfan was globally banned under the Stockholm Convention in May 2011. However, despite the ban on it use, endosulfan is still used and manufactured for export in some countries [26] . In this study, 6 cases of acute endosulfan poisoning developed in a single hospital between 2014 and 2016 despite it being banned at 2011. In the year 2016, cases of acute poisoning in domestic animals and occupational poisoning in farmers were reported in Italy and Colombia, respectively [27, 28] . Several studies demonstrated endosulfan persistence in the environment, such as water and soil, after banning due to its low water solubility [29] . These facts suggest that the banning of endosulfan might not completely eliminate endosulfan poisoning in humans. Because Englishlanguage research has not previously investigated the characteristics of seizures related to endosulfan poisoning in humans and because treatment for SE-related endosulfan poisoning has not been established, the distinguishing characteristics of seizures related to endosulfan poisoning demonstrated in this study (high progression to SE and RSE, and high potential for survival without neurologic sequelae despite prolonged RSE, the superiority of lorazepam as a first-line AED drug) could help clinicians treat seizure, which is the most common symptom of endosulfan poisoning, and allow for predicting outcomes [1, 3, 4] .
This study has several limitations. First, because EEG monitoring was performed for only a few patients, patients with nonconvulsive SE in comas might have been categorized into the nonseizure group. However, all of the patients who were in the nonseizure group were discharged with a GOS of 5 ( Fig. 1) . Second, because of the retrospective design, there were differences in the choice of AED and in the order of AEDs administered as second-line agents in seizure with refractoriness to BZD. In practice, these AEDs were used sequentially or in combination. However, there is no recommendation regarding the choice of AED if BZD fails to control seizures [8, 30] . Furthermore, treatment that deviates from the guidelines does not influence the outcome of SE [31] .
Conclusions
Seizure-related endosulfan poisoning was found to have higher progression rates to SE and RSE and higher fatality rates than other drug-induced seizures. However, delayed neurologic sequelae after discharge were not demonstrated. GCS scores at presentation are an independent predictor of progression from seizure-related endosulfan poisoning to SE and from SE-related endosulfan poisoning to RSE. Lorazepam administration curbed the progression of SE-related endosulfan poisoning to RSE. Patients presenting with low GCS scores and seizures require aggressive treatment, particularly with lorazepam, which might be considered a first-line drug. Further studies are needed to assess the optimal management of SE and to identify the prognostic factors for RSE.
